SCHEMBL19783219

SCHEMBL19783219

COC(=O)/C=C/c1ncc(N=C(c2ccccc2)c2ccccc2)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.43
KMT2A Q03164 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MAPT P10636 6/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
LMNA P02545 1/20 0.38
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
TYR P14679 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
CA14 Q9ULX7 1/20 0.37
ALDH1A1 P00352 2/20 0.37
MEN1 O00255 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9952222 0.76 TSHR (0.49) KDM4ESMN1; SMN2MAPTNPC1RAB9A
SCHEMBL19782299 0.75 ESR1 (0.42) KDM4EKMT2ASMN1; SMN2MAPTNPC1
SCHEMBL22092230 0.71 CA12 (0.47) KDM4EKMT2ASMN1; SMN2MAPTNPC1
SCHEMBL22092229 0.71 CA12 (0.47) KDM4EKMT2ASMN1; SMN2MAPTNPC1
SCHEMBL6878322 0.68 KDM4E (0.62) KDM4EKMT2ASMN1; SMN2MAPTNPC1
SCHEMBL6878313 0.68 KDM4E (0.62) KDM4EKMT2ASMN1; SMN2MAPTNPC1
SCHEMBL19783218 0.66 GRM5 (0.46) KDM4EKMT2AMAPTNPC1RAB9A
E-Methyl Cinnamate SCHEMBL901224 0.66 CA12 (0.69) KDM4EKMT2ASMN1; SMN2MAPTLMNA
E-Methyl Cinnamate SCHEMBL101530 0.66 CA12 (0.69) KDM4EKMT2ASMN1; SMN2MAPTLMNA
E-Methyl Cinnamate SCHEMBL1862419 0.66 CA12 (0.69) KDM4EKMT2ASMN1; SMN2MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109689647-B Bicyclic heteroaryl substituted compounds 百时美施贵宝公司 2023-01-20 CN disclosed
EP-3484878-B1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2020-08-19 EP disclosed
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BISTOL MYERS SQUIBB COMPANY (US) 2019-09-26 US disclosed
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BISTOL MYERS SQUIBB COMPANY (US) 2019-09-26 US disclosed
WO-2018013774-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, PF4 KDM4E 1865/4885KMT2A 2420/4885SMN1; SMN2 3677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.